Cannabis Archives - InvestorWire (IW)

Tuesday Apr 16, 2024 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024

Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41 Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended Lexaria’s management plans to maintain focus on GLP-1 studies for 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery…

Friday Apr 12, 2024 - 11:15 am

Golden Triangle Ventures Inc. (GTVH) Announces CEO Interview Series, Partners with Consulting Company on Flagship Destino Ranch Project

CEO interview series provides Golden Triangle with a platform to share its story with an expanded audience Collaboration with Cayenne Consulting will provide key strategic planning and expertise in development of Destino Ranch Destino Ranch aims to redefine luxury entertainment and hospitality experiences As Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, focus on the development of Destino Ranch, a one-of-a-kind immersive…

Thursday Mar 28, 2024 - 9:00 am

Astrotech Corp. (NASDAQ: ASTC) and AgLAB Inc. Use Mass Spectrometer Technology to Significantly Enhance Hemp and Cannabis Production Yield and Profit

The cannabinoid market value in 2023 was $22.23 billion and is expected to grow at a CAGR of 15.3%, resulting in an estimated market value of $60.36 billion The global mass spectrometry market will reach $6.77 billion in 2024 and is expected to grow at a CAGR of 6.25%, reaching $9.17 billion by 2029. Astrotech and subsidiary AgLAB Inc. are using mass spectrometry to boost…

Monday Mar 25, 2024 - 12:45 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, recently hired a Contract Research Organization to perform their second GLP-1 human pilot study which will test a dissolvable DehydraTECH-GLP-1 oral dose formulation The announcement follows Lexaria’s WEIGHT-A24-1 animal study announcement examining diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and cannabidiol alone and in combination The move aligns with the company’s resolve to focus on…

Monday Mar 25, 2024 - 12:00 pm

Software Effective Solutions Corp. (SFWJ) Completes Key Acquisitions, Is Committed to Becoming Cannabis Market Leader

MedCana adds to portfolio with strategic acquisition of two cannabis companies First acquisition represents “leap forward” in SFWJ’s commitment to innovation, excellence within the cannabis sector Second company holds key production, processing and exportation licenses that will strengthen MedCana’s operational chain Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is growing its footprint in the cannabis space through savvy acquisitions. In the past few months, MedCana,…

Monday Mar 25, 2024 - 10:30 am

Zoned Properties Inc. (ZDPY) Seizing Real Estate Opportunities in Growing Cannabis Industry

Cannabis industry retail opportunities growing amid evolving regulations, increasing consumer demand, and shifting public attitudes Demand for specialized, direct-to-consumer properties includes dispensaries, manufacturing or processing centers, and distribution hubs ZDPY is a technology-driven property investment company that focuses on securing direct-to-consumer real estate opportunities in the regulated cannabis market ZDPY has recently secured and acquired investment properties in Michigan, Arizona, and Illinois with 100% occupancy…

Thursday Mar 21, 2024 - 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study

Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD The study will comprise 12 arms and involve 72…

Friday Mar 08, 2024 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth

Lexaria, a global innovator in drug delivery platforms, has, since 2016, proven its patented DehydraTECH(TM) technology, asserting its superiority in improving drug bioavailability This has earned it 39 granted patents, with many pending globally DehydraTECH has a number of potential pharmaceutical applications with successful early stage results in hypertension, diabetes and weight loss and many others With its focus on GLP-1 clinical studies for 2024,…

Tuesday Feb 20, 2024 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D

Lexaria, a global innovator in drug delivery platforms to enhance bioavailability, announced recently that it will focus on GLP-1 applications for diabetes and weight loss for the 2024 calendar year Chris Bunka, Lexaria’s CEO, has expressed his confidence in the company’s direction, reiterating the intention to demonstrate the superior performance of GLP-1 drugs processed with its patented DehydraTECH(TM) technology The company looks to build on…

Wednesday Feb 14, 2024 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial

Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology, specifically DehydraTECH-CBD, in hypertensive patients Lexaria expects to build on success of its previous studies, which showed positive results and DehydraTECH-CBD’s potential to…

Monday Feb 12, 2024 - 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter

Lexaria, a global innovator in drug delivery platforms, just announced ambitious plans for the 2024 calendar year The letter confirms that the 2024 plans have been made possible by significant strides that were made by the company in 2023 Lexaria looks to build on the momentum gained from the previous year, ultimately asserting market dominance and making 2024 its best year yet Lexaria Bioscience (NASDAQ:…

Monday Feb 05, 2024 - 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Positioning TRACER 1000(TM) as Next-Generation Solution for the Explosive Trace Detector Market

1st Detect, a wholly owned subsidiary of mass spectrometry company Astrotech, is offering its breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”) in markets that accept ECAC certification The TRACER 1000(TM) ETD is designed to outperform ETDs currently used at airports, cargo and other secured facilities, as well as at borders Astrotech is working to position its product as the next-generation solution for the ETD market…

Thursday Feb 01, 2024 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap

Lexaria, a global innovator in drug delivery platforms, has laid down its GLP-1 human and animal studies roadmap for the 2024 calendar year This builds on the success of its human pilot study, which marked a successful undertaking for exploring its patented DehydraTECH(TM) technology for the improved delivery of the GLP-1 drug semaglutide, available commercially in the branded product Rybelsus(R) The company’s chronic dosing animal…

Monday Jan 29, 2024 - 9:45 am

Software Effective Solutions Corp. (SFWJ) Stands to Benefit If DEA Reschedules Cannabis

A coalition of military veterans’ organizations is joining a growing number of entities encouraging the U.S. DEA to reschedule cannabis The call to reschedule cannabis has gained momentum since the U.S. HHS sent a letter to the DEA supporting the change Operating as MedCana, Software Effective Solutions has five divisions focused on pharmaceutical cannabis production A growing number of organizations are calling for the rescheduling…

Tuesday Jan 23, 2024 - 9:45 am

Astrotech Corp. (NASDAQ: ASTC) Subsidiary AgLAB: Breakthrough Technology For Ag-Distillers

Astrotech subsidiary AgLAB demonstrates the capability of significant improvements in yields for large scale producers of hemp and cannabis CBD-THC oils using breakthrough mass spectrometry technology The company’s AgLAB 1000-D2(TM) mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP(TM)”) allows large-scale distillers to analyze oils during processing, and make real-time adjustments to boost yields and potencies Field trials resulted in improved ending-weight yields…

Wednesday Jan 17, 2024 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study

Lexaria, a global specialist in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 on the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of GLP-1 drug, semaglutide The results showed improved delivery of semaglutide to the bloodstream, with the drug showing approximately 44% higher levels than the control 24 hours after ingestion of a single…

Wednesday Dec 27, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology

Lexaria, a global innovator in drug delivery platforms, has made incredible strides in 2023, most recently seeing interim results from its human pilot study evaluating its DehydraTECH(TM) technology for the oral delivery of GLP-1 drug, semaglutide The company has also grown its patent portfolio to 37, with many others pending worldwide For 2024, the company expects to maintain the same momentum, building on the success…

Thursday Dec 21, 2023 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To File its IND Application with the FDA for its planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria, a global innovator in drug delivery platforms, expects to submit its IND application for its planned U.S. Phase 1b Hypertension Clinical Trial with the FDA within the next 45 days The HYPER-H23-1 clinical study will build on five successful human clinical trials conducted so far, studying the company’s patented DehydraTECH(TM)-processed CBD in an aggregate total of 134 individuals Lexaria’s patented DehydraTECH(TM) “drug delivery platform…

Wednesday Dec 13, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Additional Revenue Opportunities for 2024; Continues to Generate New Data for its DehydraTECH Technology

Lexaria, a global innovator in drug delivery platforms, is projected by Zacks SCR to be valued at $10 a share, up from the current $1.50 for 2024 Zacks SCR projects a 259% YOY revenue growth for 2024 and a 20% growth for 2025, dependent upon the ultimate approval and commercialization of products employing its patented DehydraTECH(TM) technology Lexaria also anticipates FDA approval for its IND…

Monday Dec 11, 2023 - 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Is ‘One to Watch’

In November 2023, the company announced a purchase order from a Romanian company for seven TRACER 1000 ETDs to be deployed in a European airport Astrotech announced in June 2023 that its board unanimously rejected an unsolicited acquisition proposal from BML Investment Partners In May 2023, the company announced a purchase order from a Romanian company for 17 TRACER 1000 ETDs, to be delivered during…

Tuesday Dec 05, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for…

Friday Dec 01, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Building a Global Presence with Superior Delivery Technology for Wide Range of Drugs and Active Pharmaceutical Ingredients

Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world With the strides made so far, Lexaria looks to grow its…

Monday Nov 27, 2023 - 9:00 am

Software Effective Solutions Corp. (SFWJ) Is ‘One to Watch’

MedCana announced in May 2023 full-scale production of non-THC cannabis for export to Europe The company earlier in 2023 commenced construction of crop production infrastructure at sites in Central and South America MedCana has engaged in talks with the government of Argentina about starting production in that country The company in 2023 acquired the assets of Tokan Corp., including an ERP software platform for the…

Tuesday Nov 14, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for potential diabetes and weight loss treatment The company hopes to make these drugs more effective with reduced side effects, and even more accessible to people living with diabetes The move is aimed to help the company partner with the behemoths…

Wednesday Nov 08, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Patented DehydraTECH(TM) Technology’s Effectiveness on GLP-1 Drugs for Potential Diabetes Treatment and Weight Loss

Lexaria, a global innovator in drug delivery platforms, recently announced plans to launch new human and animal studies examining whether its patented DehydraTECH(TM) technology can make GLP-1 drugs better Lexaria has previously demonstrated DehydraTECH’s overall potential in its DIAB-A22-1 animal study, which yielded weight loss, and improved triglyceride and cholesterol levels among diabetic-conditioned animals The company plans to replicate the results from this study while…

Tuesday Oct 31, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn

Lexaria, a global innovator in drug delivery platforms, just announced an exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology Lexaria will also perform specific DehydraTECH-related manufacturing operations on SulfoSyn’s behalf for an initial term of 2 years The license agreement adds to Lexaria’s growing list, which, as of the last two years, includes BevNology LLC, Premier Wellness Science Co. Ltd., and Dehydr8,…

Thursday Oct 26, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors

Lexaria has continuously taken steps to protect its intellectual property internationally to safeguard the applicability of its patented DehydraTECH(TM) technology across the globe The company recently announced that it had received two new Canadian patents, increasing to 37 the number of granted patents in its intellectual property (“IP”) portfolio Lexaria has filed tens of patent applications in multiple jurisdictions that are considered to have the…

Thursday Oct 19, 2023 - 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Raised $1.6 Million in Latest Investment Round; Looks to Advance DehydraTECH(TM) Research Operations

Lexaria, a global innovator in drug delivery platforms, recently announced that it had entered into a securities purchase agreement with a single health-focused institutional investor The agreement is for the purchase of 1,618,330 shares of common stock at $0.97 per share, with gross proceeds amounting to approximately $1.6 million The raised funds will be integral to Lexaria advancing its operations, inching it closer to FDA…

Monday Oct 16, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs

Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022 Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to…

Friday Sep 29, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application

Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets…

Thursday Sep 21, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Demonstrate DehydraTECH-CBD Benefits in Upcoming Investigational New Drug Application Submission

Lexaria’s IND application builds on five previous human clinical studies showing zero serious adverse effects and evidencing a reduction in resting blood pressure in test subjects DehydraTECH(TM)-CBD has the potential to have pronounced clinical benefits relative to the available anti-hypertensive therapeutics on the market today Work mostly under Lexaria’s control was completed earlier this year, including the batch manufacturing of DehydraTECH-CBD and placebo materials necessary…

Monday Sep 18, 2023 - 10:30 am

420 Expo 2023: Celebrating the Cannabis Culture

Cannabis enthusiasts, investors, decision-makers, and business owners, are invited to attend the 420 Expo 2023 to be held in New Jersey Expo Center, Edison, NJ from September 29 – October 1, 2023. The electrifying event is set to blaze the ever-evolving cannabis landscape, including medical experts discussing the therapeutic potential of cannabis and professionals sharing their success stories. 420 Expo 2023 is a one-of-a-kind gathering…

Friday Sep 15, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria’s IND application for its U.S. Phase 1b Hypertension Clinical Study, HYPER-H23-1, remains on track despite setbacks Work mostly under Lexaria’s control was completed earlier this year, while work that is outside its control remains delayed Regardless, Lexaria continues to make progress, even as it looks to take advantage of the growing global cardiovascular drugs market, which is projected to post a CAGR of 3.1%…

Tuesday Sep 12, 2023 - 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Investigational Research Programs Position the Company for Important Partnership Opportunities and Growth

Lexaria Bioscience has completed several studies that confirm and support the superiority and advantages of its patented DehydraTECH(TM) technology over traditional oral delivery methods The company recently announced results from its human oral nicotine study NIC-H22-1 comparing its DehydraTECH-nicotine pouch to world-leading brands, Zyn(R) and on!(R) Results from the study demonstrated that DehydraTECH-nicotine was statistically significantly faster in reaching Tmax than both brands Lexaria has…

Tuesday Sep 05, 2023 - 11:15 am

NECANN’s New York Cannabis & Hemp Convention Set to Empower the Cannabis Industry

Investors, business executives, researchers, and industry leaders, are invited to attend NECANN’s New York Cannabis & Hemp Convention to be held in Albany, New York from September 29 – 30, 2023. The highly anticipated event will focus on the latest trends in the cannabis and hemp industry. The convention serves as a unique platform to connect with industry leaders and explores the limitless possibilities within…

Friday Sep 01, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems

The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year 95% of Americans with diabetes are diagnosed with type 2 diabetes, which can lead to heart disease, stroke, kidney damage, and nerve damage when left untreated Lexaria’s DIAB-A22-1 pre-clinical diabetes study using DehydraTECH(TM)-CBD in obese diabetic-conditioned animals shows promising results, prompting…

Thursday Aug 31, 2023 - 10:30 am

Alternative Products Expo: Innovation and Sustainability

Financial analysts, savvy investors, business owners, researchers, and pioneers, are invited to attend Alternative Products Expo to be held at the World Market Center, Las Vegas from September 14-16, 2023. Las Vegas plays host to thousands of esteemed events every year, and there are several reasons for this: state-of-the-art hospitality, top-notch facilities, year-round sunshine, and world-class dining and entertainment options. Featuring one-of-a-kind nightlife, the city…

Tuesday Aug 29, 2023 - 9:45 am

NECANN’s 4th Annual New Jersey Cannabis Convention Is The Perfect Setting to Learn Everything about the Cannabis Industry

The largest B2B cannabis industry event in New Jersey – NECANN’s New Jersey Cannabis Convention – returns to Atlantic City on September 8-9, 2023. Now in its 4th year, the event, which is part of the largest cannabis and hemp convention series in the world, continues to grow as the New Jersey cannabis market develops. It comes more than a year after the state legalized…

Tuesday Aug 22, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1

Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives The study, which involved 36 participants, embraced a randomized, double-blind, cross-over study design It also affirmed Lexaria's product superiority while also showing DehydraTECH’s potential Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note…

Monday Aug 21, 2023 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Strategic Updates Concerning Patented DehydraTECH(TM) Technology

Lexaria's human oral nicotine study, NIC-H22-1, comparing world-leading brands and the company's DehydraTECH(TM)-Nicotine tobacco-free pouch, reported positive results, including higher pleasurable effects and reduced negative effects A new patent has been granted to Lexaria and is strategically important to the company's oral nicotine sector research and development efforts Lexaria continues to research diabetes control and weight loss with its DehydraTECH(TM)-CBD, announcing favorable animal study results…

Articles

Articles Category: Cannabis

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions